Green tea extract for treatment of cancers
| Autor: | Kai Cheng, Nan-Nan Chi, Jun-Dong Liu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
safety
Research design efficacy MEDLINE Antineoplastic Agents Green tea extract Bioinformatics 03 medical and health sciences 0302 clinical medicine systematic review Neoplasms Study Protocol Systematic Review Humans cancer Medicine 030212 general & internal medicine green tea extract Randomized Controlled Trials as Topic Protocol (science) Tea Plant Extracts business.industry General Medicine Research Design 030220 oncology & carcinogenesis Meta-analysis business Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 4201-9125 |
| DOI: | 10.1097/md.0000000000015117 |
| Popis: | Background: Previous clinical studies suggested that green tea extract (GTE) may benefit patients with a variety of cancers. However, its efficacy is still inconclusive. Thus, the objective of this study will systematically collate the clinical studies testing its efficacy and safety for cancers. Methods: We will perform a systematic review of clinical studies assessing the efficacy of GTE in variety of cancers. We will search Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDILINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Allied and Complementary Medicine Database (AMED), and Chinese Biomedical Literature Database (CBM) using a comprehensive strategy. We will also screen the reference lists of relevant studies to identify any additional studies for potential inclusion. All databases will be searched up to February 1, 2019. All eligible case-control studies and randomized controlled trials will be included in this study. Two independent authors will review all searched literature. Upon inclusion of trials, we will extract data by using a predefined standardized form. The risk of bias assessment will be evaluated by using Cochrane risk of bias tool. We will use RevMan 5.3 software to pool the data and carry out meta-analysis. Results: The primary outcome includes overall response rate. The secondary outcomes comprise of overall survival, progression-free survival, the disease control rate, and any adverse events. Conclusions: The results of this study will contribute to the understanding of the efficacy of GTE in the setting of cancers and promote future research of GTE in patients with cancers. Dissemination and ethics: The results of this systematic review are expected to be published through peer-reviewed journals. This study does not need ethic approval, because it does not utilize individual patient data. Systematic review registration: PROSPERO CRD42019125111. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|